Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

vigabatrin (Rx)Brand and Other Names:Sabril

 
 
 

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 500mg

powder for oral solution

  • 500mg/packet
more...

Complex Seizures

Indicated for adjunctive therapy in adults with refractory complex partial seizures

500 mg PO q12hr initially, THEN increase by 500-mg increments qWeek to target dose of 1.5 g q12hr

No additional benefit shown with 6 g daily compared with 3 g daily; higher incidence of adverse effects associated with 6 g daily

Renal Impairment

CrCl >50-80 mL/min: Decrease dose by 25%

CrCl >30-50 mL/min: Decrease dose by 50%

CrCl >10 to <30 mL/min: Decrease dose by 75%

Hemodialysis: Clearance not adequately studied

Administration

Oral solution preparation: Dissolve powder content from each 500 mg packet in 10 mL cold or room temp water (final concentration 50 mg/mL); prepare immediately before use

May take with or without food

Discontinuing: Taper by decreasing daily dose 1000 mg/day on a weekly basis until discontinued

Dosage Forms & Strengths

tablet

  • 500mg

powder for oral solution

  • 500mg/packet
more...

Partial Seizures

Indicated for adjunctive therapy in children 10-16 years of age with refractory complex partial seizures

<10 years: Safety and efficacy not established

10-16 years

  • 25-60 kg: 250 mg PO q12hr initially, THEN increase qWeek to total maintenance dose of 1000 mg q12hr
  • >60 kg: 500 mg PO q12hr initially, THEN increase by 500-mg increments qWeek to target dose of 1.5 g q12hr

>16 years

  • 500 mg PO q12hr initially, THEN increase by 500-mg increments qWeek to target dose of 1.5 g q12hr

Infantile Spasms

Indicated as monotherapy for pediatric patients with infantile spasms aged 1 month to 2 years for whom the potential benefits outweigh the potential risk of vision loss

<1 month: Not established

1 month to 2 years: 50 mg/kg/day PO divided q12hr initially; if needed, may increase dose by 25-50 mg/kg/day increments every 3 days; not to exceed 150 mg/kg/day  

Renal Impairment

Infants: Information about how to adjust dose not available

≥10 years

  • CrCl >50-80 mL/min: Decrease dose by 25%
  • CrCl >30-50 mL/min: Decrease dose by 50%
  • CrCl >10 to <30 mL/min: Decrease dose by 75%
  • Hemodialysis: Clearance not adequately studied

Administration

Oral solution preparation: Dissolve powder content from each 500 mg packet in 10 mL cold or room temp water (final concentration 50 mg/mL); prepare immediately before use

May take with or without food

Discontinuing

  • Infantile spasms: Taper by decreasing daily dose at a rate of 25-50 mg/kg q3-4 days
  • Pediatric patients aged 10-16 yr with complex partial seizures: Taper by decreasing daily dose by one-third qWeek for 3 wk
  • Pediatric patients >16 yr with complex partial seizures: Taper by decreasing daily dose 1000 mg/day on a weekly basis until discontinued

Initiate at low end of dosing range and consider dose adjustment with renal impairment

Refractory Complex Seizures

500 mg PO q12hr initially, THEN increase by 500-mg increments qWeek to target dose of 1.5 g q12hr

No additional benefit shown with 6 g daily compared with 3 g daily; higher incidence of adverse effects associated with 6 g daily

Next

Interactions

Interaction Checker

vigabatrin and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Weight gain, children (47%)

            Permanent bilateral concentric visual field constriction (>30%)

            Fatigue (28%)

            Somnolence (24%)

            Headache (18%)

            Weight gain, adults (17%)

            Dizziness (15%)

            Convulsion (11%)

            Hyperactivity, in children (11%)

            1-10%

            Nasopharyngitis (10%)

            Weight increased (10%)

            Upper respiratory tract infection (10%)

            Visual field defect (9%)

            Depression (8%)

            Tremor (7%)

            Nystagmus (7%)

            Nausea (7%)

            Diarrhea (7%)

            Memory impairment (7%)

            Insomnia (7%)

            Irritability (7%)

            Coordination abnormal (7%)

            Vision blurred (6%)

            Diplopia (6%)

            Vomiting (6%)

            Influenza (6%)

            Pyrexia (6%)

            Rash (6%)

            Postmarketing Reports

            Birth defects: Congenital cardiac defects, congenital external ear anomaly, congenital hemangioma, congenital hydronephrosis, congenital male genital malformation, congenital oral malformation, congenital vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect, low set ears, renal aplasia, retinitis pigmentosa, supernumerary nipple, talipes

            Ear disorders: Deafness

            Endocrine disorders: Delayed puberty

            Gastrointestinal disorders: Gastrointestinal hemorrhage, esophagitis

            General disorders: Developmental delay, facial edema, malignant hyperthermia, multiorgan failure

            Hepatobiliary disorders: Cholestasis

            Nervous system disorders: Dystonia, encephalopathy, hypertonia, hypotonia, muscle spasticity, myoclonus, optic neuritis

            Psychiatric disorders: Acute psychosis, apathy, delirium, hypomania, neonatal agitation, psychotic disorder

            Respiratory disorders: Laryngeal edema, pulmonary embolism, respiratory failure, stridor

            Skin and subcutaneous tissue disorders: Angioedema, maculopapular rash, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis

            Vision disorders: Permanent vision loss

            Previous
            Next

            Warnings

            Black Box Warnings

            Causes permanent vision loss in infants, children, and adults and includes progressive and permanent bilateral concentric visual field constriction in >30% of patients and ranges in severity from mild to severe, including tunnel vision to within 10 degrees of visual fixation, and can result in disability

            May damage the central retina and decrease visual acuity

            Vision loss onset is unpredictable and can occur within weeks of starting treatment, or sooner, or at any time during treatment (even after months or years), and possibly after vigabatrin is discontinued

            Vision assessment is recommended at baseline (no later than 4 weeks after initiating therapy), at least every 3 months during therapy, and about 3-6 months after discontinuation of therapy

            Consider drug discontinuation, balancing benefit and risk, if vision loss documented

            Symptoms of vision loss are unlikely to be recognized by patients or caregivers before vision loss is severe

            Risk of new or worsening vision loss continues throughout therapy; it is possible that vision loss can worsen despite discontinuation of therapy

            Therapy should not be administered to patients with, or at high risk of, other types of irreversible vision loss unless benefits of treatment clearly outweigh risks

            Use lowest dosage and shortest exposure to therapy

            Because of risk of permanent vision loss, therapy is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SABRIL REMS Program; 1-888-457-4273

            Contraindications

            Hypersensitivity

            Cautions

            P450 CYP2C inducer; coadministration with CYP2C substrates (eg, phenytoin) result in decreased plasma levels, phenytoin levels decreased 16-20% when coadministered and therefore may require dosage adjustments

            When coadministration with other AEDs, serum concentration of phenobarbital was reduced 8-16% and sodium valproate concentration was reduced by 8%

            Vigabatrin increased clonazepam Cmax by 30% and decreased Tmax by 45%

            May cause severe visual changes requiring regular ophthalmic monitoring (see Black Box Warnings)

            May cause somnolence and fatigue

            Abnormal MRI signal changes reported in some infants

            Antiepileptic drugs may increase risk of suicidal thoughts and behavior

            Taper dose gradually when discontinuing to avoid withdrawal seizures; if withdrawal needed because of serious adverse event, rapid discontinuation can be considered

            Anemia reported

            Peripheral neuropathy reported

            Weight gain reported in adults and children

            Edema reported in adults

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C; Based on animal data, may cause fetal harm

            Lactation: excreted in breast milk, do not nurse

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Irreversible inhibitor of gamma aminobutyric acid (GABA) transaminase, thereby increases the level of the inhibitory neurotransmitter GABA within the brain

            Pharmacokinetics

            Half-Life: 5.7 hr in infants; 5-8 hr in young adults; 7.5 hr in adults; 12-14 hr in geriatric patients

            Absorption: 100% (solution and tablets are bioequivalent to one another and may be interchanged)

            Vd: 1.1 L/kg  

            Peak Plasma Time: [fasting] 2.5 hr; [with food] 2 hr

            Protein Bound:  Negligible

            Metabolism: Not extensively metabolized

            Clearance: [adults] 7 L/hr; [infants] 2.4 L/hr; [children] 5.7 L/hr

            Excretion: Urine: 95%

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.